: Viking Therapeutics stock gets boost from positive news that obesity drugs reduced risk of heart attacks and strokes

Biotech’s stock is up 13% in the week to date after Novo Nordisk said its Wegovy obesity treatment reduced the risk of cardio events by 20% in obese adults.

Previous post Market Extra: Why fuel inflation ‘whack-a-mole’ may complicate Fed’s job in months ahead
Next post The Ratings Game: Rocket Lab is ‘one of the highest-quality space companies’ in the market, analyst says